These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18633187)

  • 1. Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
    Namikoshi T; Tomita N; Satoh M; Haruna Y; Kobayashi S; Komai N; Sasaki T; Kashihara N
    Hypertens Res; 2008 Apr; 31(4):745-55. PubMed ID: 18633187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.
    Omasu F; Oda T; Yamada M; Yoshizawa N; Yamakami K; Sakurai Y; Miura S
    Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1292-8. PubMed ID: 17670902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein.
    Namikoshi T; Tomita N; Satoh M; Haruna Y; Kobayashi S; Komai N; Sasaki T; Kashihara N
    Am J Hypertens; 2007 Oct; 20(10):1085-91. PubMed ID: 17903692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain.
    Schmerbach K; Schefe JH; Krikov M; Müller S; Villringer A; Kintscher U; Unger T; Thoene-Reineke C
    Brain Res; 2008 May; 1208():225-33. PubMed ID: 18378216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
    Chung S; Park CW; Shin SJ; Lim JH; Chung HW; Youn DY; Kim HW; Kim BS; Lee JH; Kim GH; Chang YS
    Nephrol Dial Transplant; 2010 Feb; 25(2):389-99. PubMed ID: 19749146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
    Sebeková K; Lill M; Boor P; Heidland A; Amann K
    Am J Nephrol; 2009; 29(3):164-70. PubMed ID: 18753741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of angiotensin II type I receptor (AT1R) protein levels in the obese Zucker rat kidney and urine.
    Hu J; Tiwari S; Riazi S; Hu X; Wang X; Ecelbarger CM
    Clin Exp Hypertens; 2009 Feb; 31(1):49-63. PubMed ID: 19172459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive renoprotective effect of candesartan and tetrahydrobiopterin in rats after 5/6 nephrectomy.
    Podjarny E; Bernheim J; Hasdan G; Karsh D; Rashid G; Green J; Katz B; Bernheim J
    Nephrol Dial Transplant; 2007 Jul; 22(7):1864-72. PubMed ID: 17442743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension.
    Nakamoto M; Ohya Y; Shinzato T; Mano R; Yamazato M; Sakima A; Takishita S
    Hypertens Res; 2008 Feb; 31(2):353-61. PubMed ID: 18360056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection.
    Yu C; Gong R; Rifai A; Tolbert EM; Dworkin LD
    J Am Soc Nephrol; 2007 Mar; 18(3):750-9. PubMed ID: 17287430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy.
    Namikoshi T; Satoh M; Tomita N; Haruna Y; Kobayashi S; Komai N; Sasaki T; Kashihara N
    Biochem Biophys Res Commun; 2007 Oct; 361(4):835-40. PubMed ID: 17681282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats.
    Yao K; Sato H; Ina Y; Suzuki K; Ohno T; Shirakura S
    Hypertens Res; 2003 Aug; 26(8):635-41. PubMed ID: 14567503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats.
    Zanchi A; Perregaux C; Maillard M; Cefai D; Nussberger J; Burnier M
    Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1228-34. PubMed ID: 16835400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist.
    Okamura M; Konishi Y; Nishimura M; Umetani N; Iwai J; Negoro N; Inoue T; Takeda T; Kanayama Y
    Blood Press Suppl; 1994; 5():75-8. PubMed ID: 7889207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats.
    Takimoto C; Kumagai H; Osaka M; Sakata K; Onami T; Kamayachi T; Iigaya K; Hayashi K; Saruta T; Itoh H
    Hypertens Res; 2008 Oct; 31(10):1941-51. PubMed ID: 19015602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition.
    Okazaki H; Minamino T; Tsukamoto O; Kim J; Okada K; Myoishi M; Wakeno M; Takashima S; Mochizuki N; Kitakaze M
    Hypertens Res; 2006 Apr; 29(4):277-84. PubMed ID: 16778335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension.
    Yokota K; Kishida M; Ogura T; Suzuki J; Otsuka F; Mimura Y; Takeda M; Nakamura Y; Makino H
    Hypertens Res; 2003 Mar; 26(3):265-72. PubMed ID: 12675283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan.
    Cervenka L; Navar LG
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S197-201. PubMed ID: 9892163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.
    Kagota S; Tada Y; Nejime N; Nakamura K; Kunitomo M; Shinozuka K
    Can J Physiol Pharmacol; 2011 May; 89(5):355-64. PubMed ID: 21619437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.
    Higashi K; Oda T; Kushiyama T; Hyodo T; Yamada M; Suzuki S; Sakurai Y; Miura S; Kumagai H
    Nephrology (Carlton); 2010 Apr; 15(3):327-35. PubMed ID: 20470302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.